Stocks Health care DXCM
NASDAQ · Health careDexcom Inc (DXCM)
Dexcom Inc brought in $5.1B of revenue over the twelve months to September 30, 2026, up 13.0% from a year earlier. Net income was $991M, a net margin of 19.4%. Operating cash flow minus capital spending left $1.1B of free cash flow in fiscal 2025. At September 30, 2026 it held $961.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Dexcom Inc
- Net worth
- Dexcom Inc has a market value (market cap) of $30.2B at the latest share price, and shareholders' equity of $2.5B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.7B (+15.6% year on year), with net income of $836.3M. Over the 12 months to September 30, 2026: revenue $5.1B, net income $991M.
- Cash flow
- In fiscal 2025 operations brought in $1.4B of cash; after $363.5M of capital spending, free cash flow was $1.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Dexcom Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Dexcom Inc does
Dexcom Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker DXCM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.7B | $836.3M | $2.09 | $1.1B |
| 2024 | $4B | $576.2M | $1.42 | $630.7M |
| 2023 | $3.6B | $541.5M | $1.30 | $511.9M |
| 2022 | $2.9B | $341.2M | $0.82 | $304.7M |
| 2021 | $2.4B | $216.9M | $0.53 | $53.3M |
| 2020 | $1.9B | $549.7M | $1.33 | $276.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where DXCM ranks in Health care
Latest SEC filings
What Dexcom Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 11% to $1.3B versus the same quarter last year; diluted EPS $0.72 versus $0.70.
- October 29, 2026
- September 14, 2026Executive or director change8-KDexcom promoted Chief Financial Officer Jereme Sylvain to the dual role of Chief Operating Officer and Chief Financial Officer.
- September 10, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 13% to $1.3B versus the same quarter last year; diluted EPS $0.64 versus $0.45.
- July 30, 2026
- May 28, 2026
- May 28, 2026
- May 15, 2026
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 15% to $1.2B versus the same quarter last year; diluted EPS $0.51 versus $0.27.
What is DXCM worth? A DCF from its reported cash flow
Insider trades
What the people running Dexcom Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.5M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Ashley Euan A.Director | Gave as a gift | 2,389 | - |
| October 27, 2026 | Stern SadieEVP Chief People & Culture Off | Soldpre-planned (10b5-1) | 2,565 | $201.7K |
| October 15, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Soldpre-planned (10b5-1) | 1,700 | $145.3K |
| September 28, 2026 | Stern SadieEVP Chief People & Culture Off | Soldpre-planned (10b5-1) | 2,565 | $221K |
| September 15, 2026 | Brown Michael JonEVP Chief Legal Compliance Off | Soldpre-planned (10b5-1) | 1,700 | $142.9K |
| September 15, 2026 | Augustinos NicholasDirector | Soldpre-planned (10b5-1), indirect | 6,539 | $549.5K |
| September 14, 2026 | Augustinos NicholasDirector | Soldpre-planned (10b5-1), indirect | 1,550 | $130.2K |
| September 10, 2026 | Sylvain Jereme MEVP, Chief Financal Officer | Soldpre-planned (10b5-1) | 3,638 | $302.9K |
Who owns DXCM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.49% | April 29, 2026 |
| Vanguard Portfolio Management13G, passive | 5.02% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 971 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 38,244,137 | -720,234 |
| Vanguard Capital Management LLC | 25,209,752 | +188,791 |
| Vanguard Portfolio Management LLC | 19,656,540 | +436,587 |
| State Street Corp | 18,380,806 | +445,959 |
| Invesco Ltd. | 15,288,133 | +1,615,819 |
| Baillie Gifford & Co | 14,801,590 | -797,935 |
| Geode Capital Management, LLC | 12,426,515 | +79,877 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 11,261,876 | +1,515,702 |
| Alliancebernstein L.P. | 11,693,409 | -1,230,235 |
| Wellington Management Group Llp | 8,527,471 | -798,769 |
| Arrowstreet Capital, Limited Partnership | 6,873,273 | +4,328,170 |
| Norges Bank | 6,868,090 | new |
| UBS Group AG | 6,065,779 | +1,715,820 |
| Amundi | 5,603,490 | -729,071 |
| Morgan Stanley | 5,156,282 | +114,238 |
| Ameriprise Financial Inc | 4,820,775 | +579,991 |
| Castle Hook Partners LP | 3,870,342 | +3,068,495 |
| Goldman Sachs Group Inc | 3,758,616 | +714,981 |
| Franklin Resources Inc | 3,595,893 | +988,455 |
| Massachusetts Financial Services Co | 3,560,621 | +1,626,169 |
Insiders
17 insiders reported holding 1,500,039 shares in total, about $119.9M at the last price.
| Holder | Shares |
|---|---|
| Leach Jacob StevenPresident, CEO, and Director, Director | 418,908 |
| Sayer Kevin RExecutive Chair, Director | 302,214 |
| Sylvain Jereme MEVP, Chief Financal Officer | 146,828 |
| Stern SadieEVP Chief People & Culture Off | 120,913 |
| Brown Michael JonEVP Chief Legal Compliance Off | 98,185 |
| Coleman JonEVP, Chief Commercial Officer | 95,450 |
| Altman Steven RDirector | 69,23263,667 held indirectly |
| Foletta Mark GDirector | 55,18348,852 held indirectly |
| Collins Richard AlexanderDirector | 45,76740,162 held indirectly |
| Augustinos NicholasDirector | 34,86829,293 held indirectly |
Questions about DXCM
What does Dexcom Inc do?
Dexcom Inc is a company in the Health care sector, listed on NASDAQ as DXCM. Its shares trade on NASDAQ under the ticker DXCM.
What is Dexcom Inc's net worth?
Dexcom Inc has a market value (market cap) of $30.2B at the latest share price, and shareholders' equity of $2.5B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Dexcom Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $991M on revenue of $5.1B, a net margin of 19.4%.
How much revenue does Dexcom Inc make?
Over the twelve months to September 30, 2026 Dexcom Inc reported revenue of $5.1B. That is 13.0% more than a year earlier.
When did Dexcom Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 3, 2026.
When is Dexcom Inc's next earnings report?
Dexcom Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DXCM with
Follow DXCM
Get an email when Dexcom Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Dexcom Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.